RG012-06: A Phase 1, Open-Label Study to Evaluate the Safety, Pharmacodynamics, and Pharmacokinetics of Subcutaneous RG-012 for Injection, Including Its Effect on Renal microRNA-21, in Subjects with Alport Syndrome

Project: Research project

Project Details

StatusActive
Effective start/end date6/4/18 → 8/31/50

Funding

  • Regulus Therapeutics Inc.